Woodford Woes Drag On For Immunocore
Unrealistic Valuations Holding Private Firms Back
Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.
You may also be interested in...
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
The UK has announced a ‘course correction’ on its vaccination program, and looks to have maintained public confidence so far – unfortunately the same cannot be said for EU countries